Second Human Pegivirus in Hepatitis C Virus–Infected and Hepatitis C Virus/HIV-1–Co-infected Persons Who Inject Drugs, China
Haiying Wang
1, Zhengwei Wan
1, Qiang Sun
1, Nalin Zhu, Tianyi Li, Xuqi Ren, Xiaoping An, Shuyun Deng, Yue Wu, Xiufen Li, Lin Li, Jingyun Li, Yigang Tong, and Shixing Tang
Author affiliations: Southern Medical University, Guangzhou, China (H. Wang, Z. Wan, N. Zhu, Y. Wu, X. Li, S. Tang); Guangdong Provincial Key Laboratory of Tropical Disease Research, Guangzhou (H. Wang, Z. Wan, N. Zhu, Y. Wu, X. Li, S. Tang); Beijing Institute of Microbiology and Epidemiology, Beijing, China (Q. Sun, T. Li, X. An, L. Li, J. Li, Y. Tong); Guangdong Provincial Dermatology Hospital, Guangzhou (X. Ren); Nanfang Hospital, Guangzhou (S. Deng)
Main Article
Figure 1
Figure 1. Detection of second human pegivirus (HPgV-2) antibodies in different samples in Guangdong and Sichuan Provinces, China. Serum or plasma samples from 86 HCV-infected patients, 70 PWID, 122 MSM, and 102 blood donors (100 samples that were negative for HPgV-2 antibodies plus 2 positive samples) are included. The antibody titers from each sample are plotted on the y-axis. HPgV-2 RNA–positive samples are shown in red. HCV, hepatitis C virus; MSM, men who have sex with men; OD450, optical density at 450 nm; PWID, persons who inject drugs.
Main Article
Page created: April 17, 2018
Page updated: April 17, 2018
Page reviewed: April 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.